Hepatitis C: New points system helps with disease prognosis

July 29, 2013, Medical University of Vienna
Hepatitis C: New points system helps with disease prognosis

Between 40,000 and 80,000 Austrians suffer from hepatitis C. With new infections the prompt and appropriate treatment is of great importance as this can prevent it developing into a chronic illness which in turn can progress to inoperable liver cancer. Now a research team led by scientists of the MedUni Vienna has succeeded in developing a points system enabling a better prognosis as to whether the illness will become chronic or whether the acute hepatitis C will spontaneously heal itself.

"This is significant by virtue of the fact that, for patients with a tendency towards developing a chronic illness, early treatment with affords a better chance of healing," explains hepatologist Harald Hofer of the University Department of Internal Medicine III at the MedUni Vienna, Clinical Department of Gastroenterology and Hepatology (Chief: Michael Trauner).

The points system was developed by the MedUni Vienna researchers from a combination of clinical and biochemical parameters. Says Hofer: "Using this, the clinical course of the acute hepatitis C can be much better predicted, which means that the costly antiviral therapy with its many side effects can be much more efficiently deployed." The results of the study have been now published in the leading Journal of Hepatology.

Towards an interferon-free therapy

The advances made in treating hepatitis are generally remarkable. Two new, direct acting antiviral substances (DAA/"Direct Acting Antiviral Therapy") have been submitted for licensing not only in Europe but also in the USA (Simeprevir and Sofosbuvir), and will, according to Hofer, also be available in the foreseeable future. "For some of the patients this means that interferon-free therapy is becoming a reality outside clinical trials as well."

Current standard treatment is a combination therapy with interferon-alpha, which possesses an immune-stimulating, . In cases of hepatitis C interferon is injected once a week over a period of up to twelve months – although with undesirable side effects such as aching limbs, fever, headaches, as well as depressive episodes or malfunctions of the thyroid. The advantage of direct (DAA) is that it acts directly on the hepatitis C virus and is thus more effective – with fewer side effects.

Explore further: Antiviral therapy may halve risk of liver cancer after chronic hepatitis C infection

More information: "A Diagnostic Score for the Prediction of Spontaneous Resolution of Acute Hepatitis C Virus Infection." Beinhardt S, Anna Payer B, Datz C, Strasser M, Maieron A, Dorn L, Grilnberger-Franz E, Dulic-Lakovic E, Stauber R, Laferl H, H Aberle J, Holzmann H, Krall C, Vogel W, Ferenci P, Hofer H. J Hepatol. 2013 Jul 10. pii: S0168-8278(13)00446-7. doi:10.1016/j.jhep.2013.06.028

Further publications:

"Effect of gender and ITPA polymorphisms on ribavirin-induced anemia in chronic hepatitis C patients." Scherzer TM, Stättermayer AF, Stauber R, Maieron A, Strasser M, Laferl H, Schwarzer R, Datz C, Rutter K, Beinhardt S, Munda P, Hofer H, Ferenci P. . J Hepatol. 2013 Jul 10. doi:pii:S0168-8278(13)00448-0. 10.1016/j.jhep.2013.06.030

"Durability of SVR in chronic hepatitis C patients treated with peginterferon-?2a/ribavirin in combination with a direct-acting anti-viral." Rutter K, Hofer H, Beinhardt S, Dulic M, Gschwantler M, Maieron A, Laferl H, Stättermayer AF, Scherzer TM, Strassl R, Holzmann H, Steindl-Munda P, Ferenci. Aliment Pharmacol Ther. 2013 Jul;38(2):118-23. doi: 10.1111/apt.12350

"Role of FDFT1 polymorphisms for fibrosis progression in patients with chronic hepatitis C." Stättermayer AF, Rutter K, Beinhardt S, Wrba F, Scherzer TM, Strasser M, Hofer H, Steindl-Munda P, Trauner M, Ferenci P. Liver Int. 2013 (in press).

Related Stories

Antiviral therapy may halve risk of liver cancer after chronic hepatitis C infection

October 22, 2012
Treating chronic hepatitis C infection with antiviral drugs could halve the risk of developing the most common form of liver cancer, in some cases, indicates an analysis of the published research in one of the new BMJ Open ...

Combination of oral drugs suppresses common type of hepatitis C

January 19, 2012
A new combination of investigational drugs successfully suppressed hepatitis C genotype 1 infection in a high percent of patients who had not responded to previous treatment in a study led by a University of Michigan hepatologist.

Chronic hepatitis C: Interferon may be harmful in re-treatment

January 30, 2013
People with hepatitis C and chronic liver disease who relapsed or failed to respond to initial treatment are unlikely to improve on interferon retreatment. In fact, they may face an increased risk of dying sooner, and are ...

Pharmaceutical advances offer new options for health outcomes

May 20, 2013
Research presented at Digestive Disease Week (DDW) explores pharmaceutical advances for treating irritable bowel syndrome with diarrhea (IBS-D) and hepatitis C.

New focus to combat rising liver disease

July 26, 2013
University of Adelaide researchers are investigating how the liver responds to hepatitis C virus (HCV) and why some people can control the virus while others can't. The aim is to find better therapies to combat hepatitis ...

Antiviral therapy may cut recurrence of hepatitis B-linked liver cancer

November 12, 2012
(HealthDay)—People with liver cancer tied to infection with the hepatitis B virus who got antiviral therapy after cancer surgery had a lower risk of tumor recurrence than those who did not get it, according to a new study.

Recommended for you

Novel molecular target to prevent scarring of the lung blood vessels identified

June 13, 2018
Pulmonary arterial hypertension, a severe form of cardiopulmonary disease in which the arteries that transport blood from the heart to the lungs become thickened, constricted, and scarred, is a disease for which there is ...

Fast-acting cholera vaccine could curb outbreaks

June 13, 2018
A tricked-out cholera vaccine starts protecting against the deadly disease within a day, experiments in rabbits suggest. The rapid protection offered by this designer vaccine may one day limit the spread of cholera outbreaks, ...

Lineage of TB traced and compared to early human migration

June 13, 2018
A team of researchers from the University of Wisconsin, the University of Iowa and the Norwegian Institute of Public Health has carried out genetic studies of tuberculosis to learn more about its lineage and to compare it ...

Finally, hope for a syphilis vaccine

June 12, 2018
Despite efforts to eradicate it, syphilis is on the rise. Until now, most health agencies focused on treating infected people and their sex partners but new discoveries may make a vaccine possible, UConn Health researchers ...

How to slow down Ebola—Virologists use 'genetic trees' to evaluate intervention strategies

June 12, 2018
The phylogenetic tree of the 2013-2016 Ebola epidemic doesn't just reveal how the Ebola virus was able to evolve—it also reveals which events and preventive measures accelerated or slowed down its spread. These findings ...

Small children and pregnant women may be underdosed in current malaria regimen

June 12, 2018
Current recommended dosing regimens for the most widely used treatment for uncomplicated Plasmodium falciparum malaria may be sub-optimal for the most vulnerable populations of patients, according to a study published this ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.